Related references
Note: Only part of the references are listed.Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis
Yong-il Kim
NUCLEAR MEDICINE COMMUNICATIONS (2021)
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis
Jonathan Strosberg et al.
CANCER TREATMENT REVIEWS (2021)
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy
Thomas A. Hope et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y
M. Pavel et al.
ANNALS OF ONCOLOGY (2020)
Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours
W. A. van der Zwan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2019)
Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
S. Rudisile et al.
BMC CANCER (2019)
68Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours
Rohini Sharma et al.
RADIOTHERAPY AND ONCOLOGY (2019)
Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response
Emily Vaughan et al.
BRITISH JOURNAL OF RADIOLOGY (2018)
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
Jonathan Strosberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
Eric Raymond et al.
NEUROENDOCRINOLOGY (2018)
Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour
Anna Yordanova et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari et al.
JAMA ONCOLOGY (2017)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander et al.
CLINICAL CANCER RESEARCH (2017)
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M. H. Kulke et al.
ANNALS OF ONCOLOGY (2017)
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Martyn E. Caplin et al.
ENDOCRINE-RELATED CANCER (2016)
Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up
Dieter Hoersch et al.
EUROPEAN JOURNAL OF CANCER (2016)
Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors: Overall Survival and Circulating Biomarkers From the Randomized, Phase III RADIANT-3 Study
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial
Aaron Vinik et al.
TARGETED ONCOLOGY (2016)
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC
Stefano Severi et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours
Amir Sabet et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
John J. Zaknun et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2013)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Dik J. Kwekkeboom et al.
ENDOCRINE-RELATED CANCER (2010)
90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
David L. Bushnell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
Martijn van Essen et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
The Pathologic Classification of Neuroendocrine Tumors A Review of Nomenclature, Grading, and Staging Systems
David S. Klimstra et al.
PANCREAS (2010)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2006)
Share Paper
